Teva Pharma, AstraZeneca seek to buy Amarin: Report
15 Nov, 2012, 06.41PM IST, Reuters

"....AstraZeneca's new CEO Pascal Soriot has acknowledged that deals will be important in rebuilding the company's drug pipeline.

Analysts have speculated that AstraZeneca, one of Europe's top drugmakers, could look at buying mid-sized specialty companies like Forest Laboratories and Shire, as well as striking smaller deals for firms such as Amarin...."


3 Potential Partners for Amarin
By Keith Speights | More Articles
November 14, 2012

"....Should an acquisition be in the cards, AstraZeneca has plenty of cash to go shopping. With the share buyback on hold, the company has $6.8 billion in cash, equivalents, and short-term investments. Amarin's current market cap is $1.6 billion...."